What is Proofpilot?
Founded in 2014 by Matthew Amsden, New York-based Proofpilot operates as a sophisticated software-as-a-service (SaaS) platform designed to democratize the execution of research studies. The company provides a dual-pronged solution: ProofPilot Rx, tailored for the rigorous demands of life science enterprises, and ProofPilot 365, which addresses the growing market for wellness interventions. By digitizing the research lifecycle, the firm enables stakeholders to design, launch, and manage studies with unprecedented efficiency, effectively bridging the gap between complex clinical requirements and user-centric digital engagement.
How much funding has Proofpilot raised?
Proofpilot has raised a total of $23.4M across 5 funding rounds:
Other Financing Round
$20K
Private Equity
$1.9M
Private Equity
$1.9M
Series B
$12M
Stock/Share Issuance
$7.7M
Other Financing Round (2014): $20K with participation from Blueprint Health
Private Equity (2014): $1.9M, investors not publicly disclosed
Private Equity (2016): $1.9M supported by Cue Ball Capital and Brooklyn Bridge Ventures
Series B (2022): $12M featuring Sopris Capital Associates, Excelra, First Trust Capital Partners, and MITSUI & CO LTD
Stock/Share Issuance (2025): $7.7M, investors not publicly disclosed
Key Investors in Proofpilot
Sopris Capital Associates
An investment firm providing long-term capital with a focus on fostering growth and creating value for businesses seeking development support.
Excelra
A leading informatics company specializing in data science and analytics services to accelerate drug discovery and improve patient outcomes.
First Trust Capital Partners
A firm specializing in early and growth-stage investments within the financial services and healthcare technology sectors.
What's next for Proofpilot?
With this latest capital deployment, Proofpilot is well-positioned to accelerate its market penetration and enhance its technological stack. The company's strategic roadmap likely involves scaling its SaaS offerings to meet the increasing demand for decentralized clinical trials and digital health monitoring. As the industry shifts toward more agile, data-driven research methodologies, Proofpilot's ability to integrate seamlessly into existing healthcare workflows will be paramount. Investors are betting on the firm's capacity to maintain its competitive edge by expanding its footprint in both the pharmaceutical and wellness sectors, ultimately driving long-term value through innovation in research automation.
See full Proofpilot company page
